SEC Form 4 · accession 0001479290-18-000004
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lauren P Silvernail
Officer — CFO, CBO & Secretary
Period of report
Dec 29, 2017
Accepted (ET)
Jan 3, 2018 · 8:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 29, 2017 | J | 443 | $22.9925 | A | 66,955 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were acquired by Mrs. Silvernail under the Issuer's 2014 Employee Stock Purchase Plan (the "Plan") on December 29, 2017 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Mrs. Silvernail purchased the maximum number of shares allowable under the Issuer's Plan and Internal Revenue Code Section 423(b)(8) for the period ended December 31, 2017.